Study #2023-1067
Impact of a prebiotic food-enriched diet (PreFED) in combination with Ipilimumab/Nivolumab combination immune checkpoint blockade (ICB) in ICB-refractory melanoma patients
MD Anderson Study Status
Enrolling
Treatment Agent
Ipilimumab, Nivolumab
Description
To learn about the possible effects of a prebiotic food-enriched diet (PreFED) targeting the gut microbiome in participants with ICI-refractory melanoma who are receiving the combination of ipilimumab and nivolumab as part of their standard care.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
ICB-refractory Melanoma
Study phase:
Phase II
Physician name:
Jennifer McQuade
Department:
Melanoma Medical Oncology
For general questions about clinical trials:
1-844-929-4217
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.